FY2025 EPS Estimates for Biotricity Cut by HC Wainwright

Biotricity, Inc. (NASDAQ:BTCY) – Equities research analysts at HC Wainwright cut their FY2025 EPS estimates for Biotricity in a note issued to investors on Monday, November 18th. HC Wainwright analyst K. Dede now anticipates that the company will post earnings per share of ($0.67) for the year, down from their previous estimate of ($0.43). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Biotricity’s current full-year earnings is ($0.67) per share.

Biotricity Trading Down 11.8 %

Shares of NASDAQ:BTCY opened at $0.28 on Wednesday. The firm has a market cap of $6.28 million, a price-to-earnings ratio of -0.23 and a beta of 1.22. Biotricity has a 1 year low of $0.19 and a 1 year high of $1.67. The business has a fifty day simple moving average of $0.34 and a 200 day simple moving average of $0.63.

Biotricity (NASDAQ:BTCY) last posted its quarterly earnings results on Monday, August 19th. The company reported ($0.49) EPS for the quarter. The firm had revenue of $3.20 million for the quarter.

Institutional Investors Weigh In On Biotricity

An institutional investor recently bought a new position in Biotricity stock. AE Wealth Management LLC bought a new stake in shares of Biotricity, Inc. (NASDAQ:BTCY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 97,751 shares of the company’s stock, valued at approximately $88,000. AE Wealth Management LLC owned approximately 0.45% of Biotricity at the end of the most recent reporting period. 3.89% of the stock is currently owned by institutional investors.

About Biotricity

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.